China Biologic Products (NASDAQ:CBPO) Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of China Biologic Products (NASDAQ:CBPO) from a hold rating to a sell rating in a research note published on Thursday morning, Zacks.com reports.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of China Biologic Products from a buy rating to a hold rating in a report on Saturday, June 1st. BidaskClub raised shares of China Biologic Products from a hold rating to a buy rating in a report on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $78.00.

NASDAQ:CBPO traded up $1.55 during mid-day trading on Thursday, reaching $98.63. 3,476 shares of the company were exchanged, compared to its average volume of 120,945. China Biologic Products has a 12 month low of $60.08 and a 12 month high of $105.50. The company has a fifty day moving average of $95.07 and a 200 day moving average of $91.08. The stock has a market cap of $3.78 billion, a PE ratio of 24.56, a PEG ratio of 4.96 and a beta of 1.26.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.21. China Biologic Products had a net margin of 29.46% and a return on equity of 8.56%. The firm had revenue of $135.70 million for the quarter. During the same period in the prior year, the company earned $1.17 EPS. The firm’s revenue was up 12.7% compared to the same quarter last year. On average, equities research analysts predict that China Biologic Products will post 3.29 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its position in China Biologic Products by 446.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,761 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 1,439 shares during the period. SG Americas Securities LLC acquired a new position in China Biologic Products during the 2nd quarter valued at about $187,000. Quantamental Technologies LLC acquired a new position in China Biologic Products during the 1st quarter valued at about $308,000. Laurion Capital Management LP acquired a new position in China Biologic Products during the 1st quarter valued at about $317,000. Finally, Parametrica Management Ltd acquired a new position in China Biologic Products during the 1st quarter valued at about $334,000. Institutional investors own 35.41% of the company’s stock.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Read More: Limitations of analyzing profit margin

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.